SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA

SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA

Abstract INTRODUCTION Glioblastoma is highly resistant to radio- and chemotherapy and its heterogeneity is a therapeutic challenge. O6-methylguanine–DNA methyltransferase (MGMT) promotor methylation is an established biomarker for favorable effect of chemotherapy. Supramaximal resection has proven p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii284-viii284
Hauptverfasser: Mendoza Mireles, Eduardo Erasmo, Blakstad, Hanne, Mughal, Awais Ahmad, Server, Andres, Brandal, Petter, Leske, Henning, Aarhus, Mads, Helseth, Eirik, Rønning, Pål Andre, Vik-Mo, Einar O
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page viii284
container_issue Supplement_8
container_start_page viii284
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Mendoza Mireles, Eduardo Erasmo
Blakstad, Hanne
Mughal, Awais Ahmad
Server, Andres
Brandal, Petter
Leske, Henning
Aarhus, Mads
Helseth, Eirik
Rønning, Pål Andre
Vik-Mo, Einar O
description Abstract INTRODUCTION Glioblastoma is highly resistant to radio- and chemotherapy and its heterogeneity is a therapeutic challenge. O6-methylguanine–DNA methyltransferase (MGMT) promotor methylation is an established biomarker for favorable effect of chemotherapy. Supramaximal resection has proven predict the best overall survival (OS), but whether this benefit applies equally to patients with different MGMT-promotor methylation status is still to be debated. MATERIAL AND METHODS Population based retrospective study that examined all adult patients in South-Eastern Norway that underwent resection for IDH wildtype glioblastoma between January 2019 and December 2021. Extent of resection (EOR) was classified according to RANO resect classification and MGMT-promotor methylation status by pyrosequencing-qPCR. RESULTS The study included 281 patients. MGMT-promotor methylated patients (MGMT+) had a median OS of 18.4 months compared to 13.1 months in MGMT-unmethylated (MGMT-) patients (p
doi_str_mv 10.1093/neuonc/noae165.1126
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_1126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.1126</oup_id><sourcerecordid>10.1093/neuonc/noae165.1126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c836-e09982be04c8a5c841b646638fcfe741ad9db586e682b986df30823434ad21843</originalsourceid><addsrcrecordid>eNqNkEFOwzAQRS0EEqVwAja-gFM7dlxnaYpJLdlJlbgFVlGaOFIRNFWiLnp7UtoDsJk_i_dHmgfAM8EBwTGd7f2x29ezfVd5wqOAkJDfgAmJQooiwfnt3x4iEZH5PXgYhi-MQxJxMgG7Yp0niM0DWKxXubTyQ1tpYK4KtXA6S6G2qzzbqAKOI5fGjFy-0ZuR0SlcSadV6gr4rt0S2sQ6tE6tcstPI516hYnR2YuRhcusfAR3bfU9-KdrToF7U26xRCZL9EIaVAvKkcdxLMKtx6wWVVQLRraccU5FW7d-zkjVxM12_MnzkYoFb1qKRUgZZVUTEsHoFNDL2brvhqH3bXnodz9VfyoJLs-yyous8iqrPMsaW8Gl1R0P_yr8AiHSZ0I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Mendoza Mireles, Eduardo Erasmo ; Blakstad, Hanne ; Mughal, Awais Ahmad ; Server, Andres ; Brandal, Petter ; Leske, Henning ; Aarhus, Mads ; Helseth, Eirik ; Rønning, Pål Andre ; Vik-Mo, Einar O</creator><creatorcontrib>Mendoza Mireles, Eduardo Erasmo ; Blakstad, Hanne ; Mughal, Awais Ahmad ; Server, Andres ; Brandal, Petter ; Leske, Henning ; Aarhus, Mads ; Helseth, Eirik ; Rønning, Pål Andre ; Vik-Mo, Einar O</creatorcontrib><description>Abstract INTRODUCTION Glioblastoma is highly resistant to radio- and chemotherapy and its heterogeneity is a therapeutic challenge. O6-methylguanine–DNA methyltransferase (MGMT) promotor methylation is an established biomarker for favorable effect of chemotherapy. Supramaximal resection has proven predict the best overall survival (OS), but whether this benefit applies equally to patients with different MGMT-promotor methylation status is still to be debated. MATERIAL AND METHODS Population based retrospective study that examined all adult patients in South-Eastern Norway that underwent resection for IDH wildtype glioblastoma between January 2019 and December 2021. Extent of resection (EOR) was classified according to RANO resect classification and MGMT-promotor methylation status by pyrosequencing-qPCR. RESULTS The study included 281 patients. MGMT-promotor methylated patients (MGMT+) had a median OS of 18.4 months compared to 13.1 months in MGMT-unmethylated (MGMT-) patients (p&lt;0.0001). Patients with supramaximal resection had a median OS of 20.4 months compared to 14.9 months (p&lt;0.01) with maximal resection. For patients with supramaximal resection we found no significant difference in median OS (25.5 vs. 18.3 months (p=0.24)) dependent on MGMT-status. Separated analysis between MGMT-status and EOR showed a median survival of 18.3, 13.4 (p&lt;0.001), and 8.5 (p&lt;0.001) months for MGMT-, and 25.5, 18.4 (p=.99), and 9.0 (p&lt;0.001) months for MGMT+ in patients where supramaximal-, maximal-, and submaximal resection was achieved, respectively. CONCLUSIONS Patients with supramaximal resection and MGMT+ have a 50% 2-years survival probability. In patients where supramaximal resection was achieved, survival benefit was not dependent on MGMT-status. There was a significant improved survival in MGMT- patients between supramaximal and maximal resection, that was not present for MGMT+ patients. Intraoperative molecular diagnosis has the potential to guide the surgical strategy dependent on MGMT-promotor methylation status, especially in tumors where supramaximal resection has a higher risk of new neurological deficits.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.1126</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii284-viii284</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mendoza Mireles, Eduardo Erasmo</creatorcontrib><creatorcontrib>Blakstad, Hanne</creatorcontrib><creatorcontrib>Mughal, Awais Ahmad</creatorcontrib><creatorcontrib>Server, Andres</creatorcontrib><creatorcontrib>Brandal, Petter</creatorcontrib><creatorcontrib>Leske, Henning</creatorcontrib><creatorcontrib>Aarhus, Mads</creatorcontrib><creatorcontrib>Helseth, Eirik</creatorcontrib><creatorcontrib>Rønning, Pål Andre</creatorcontrib><creatorcontrib>Vik-Mo, Einar O</creatorcontrib><title>SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract INTRODUCTION Glioblastoma is highly resistant to radio- and chemotherapy and its heterogeneity is a therapeutic challenge. O6-methylguanine–DNA methyltransferase (MGMT) promotor methylation is an established biomarker for favorable effect of chemotherapy. Supramaximal resection has proven predict the best overall survival (OS), but whether this benefit applies equally to patients with different MGMT-promotor methylation status is still to be debated. MATERIAL AND METHODS Population based retrospective study that examined all adult patients in South-Eastern Norway that underwent resection for IDH wildtype glioblastoma between January 2019 and December 2021. Extent of resection (EOR) was classified according to RANO resect classification and MGMT-promotor methylation status by pyrosequencing-qPCR. RESULTS The study included 281 patients. MGMT-promotor methylated patients (MGMT+) had a median OS of 18.4 months compared to 13.1 months in MGMT-unmethylated (MGMT-) patients (p&lt;0.0001). Patients with supramaximal resection had a median OS of 20.4 months compared to 14.9 months (p&lt;0.01) with maximal resection. For patients with supramaximal resection we found no significant difference in median OS (25.5 vs. 18.3 months (p=0.24)) dependent on MGMT-status. Separated analysis between MGMT-status and EOR showed a median survival of 18.3, 13.4 (p&lt;0.001), and 8.5 (p&lt;0.001) months for MGMT-, and 25.5, 18.4 (p=.99), and 9.0 (p&lt;0.001) months for MGMT+ in patients where supramaximal-, maximal-, and submaximal resection was achieved, respectively. CONCLUSIONS Patients with supramaximal resection and MGMT+ have a 50% 2-years survival probability. In patients where supramaximal resection was achieved, survival benefit was not dependent on MGMT-status. There was a significant improved survival in MGMT- patients between supramaximal and maximal resection, that was not present for MGMT+ patients. Intraoperative molecular diagnosis has the potential to guide the surgical strategy dependent on MGMT-promotor methylation status, especially in tumors where supramaximal resection has a higher risk of new neurological deficits.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkEFOwzAQRS0EEqVwAja-gFM7dlxnaYpJLdlJlbgFVlGaOFIRNFWiLnp7UtoDsJk_i_dHmgfAM8EBwTGd7f2x29ezfVd5wqOAkJDfgAmJQooiwfnt3x4iEZH5PXgYhi-MQxJxMgG7Yp0niM0DWKxXubTyQ1tpYK4KtXA6S6G2qzzbqAKOI5fGjFy-0ZuR0SlcSadV6gr4rt0S2sQ6tE6tcstPI516hYnR2YuRhcusfAR3bfU9-KdrToF7U26xRCZL9EIaVAvKkcdxLMKtx6wWVVQLRraccU5FW7d-zkjVxM12_MnzkYoFb1qKRUgZZVUTEsHoFNDL2brvhqH3bXnodz9VfyoJLs-yyous8iqrPMsaW8Gl1R0P_yr8AiHSZ0I</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Mendoza Mireles, Eduardo Erasmo</creator><creator>Blakstad, Hanne</creator><creator>Mughal, Awais Ahmad</creator><creator>Server, Andres</creator><creator>Brandal, Petter</creator><creator>Leske, Henning</creator><creator>Aarhus, Mads</creator><creator>Helseth, Eirik</creator><creator>Rønning, Pål Andre</creator><creator>Vik-Mo, Einar O</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA</title><author>Mendoza Mireles, Eduardo Erasmo ; Blakstad, Hanne ; Mughal, Awais Ahmad ; Server, Andres ; Brandal, Petter ; Leske, Henning ; Aarhus, Mads ; Helseth, Eirik ; Rønning, Pål Andre ; Vik-Mo, Einar O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c836-e09982be04c8a5c841b646638fcfe741ad9db586e682b986df30823434ad21843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mendoza Mireles, Eduardo Erasmo</creatorcontrib><creatorcontrib>Blakstad, Hanne</creatorcontrib><creatorcontrib>Mughal, Awais Ahmad</creatorcontrib><creatorcontrib>Server, Andres</creatorcontrib><creatorcontrib>Brandal, Petter</creatorcontrib><creatorcontrib>Leske, Henning</creatorcontrib><creatorcontrib>Aarhus, Mads</creatorcontrib><creatorcontrib>Helseth, Eirik</creatorcontrib><creatorcontrib>Rønning, Pål Andre</creatorcontrib><creatorcontrib>Vik-Mo, Einar O</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mendoza Mireles, Eduardo Erasmo</au><au>Blakstad, Hanne</au><au>Mughal, Awais Ahmad</au><au>Server, Andres</au><au>Brandal, Petter</au><au>Leske, Henning</au><au>Aarhus, Mads</au><au>Helseth, Eirik</au><au>Rønning, Pål Andre</au><au>Vik-Mo, Einar O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii284</spage><epage>viii284</epage><pages>viii284-viii284</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract INTRODUCTION Glioblastoma is highly resistant to radio- and chemotherapy and its heterogeneity is a therapeutic challenge. O6-methylguanine–DNA methyltransferase (MGMT) promotor methylation is an established biomarker for favorable effect of chemotherapy. Supramaximal resection has proven predict the best overall survival (OS), but whether this benefit applies equally to patients with different MGMT-promotor methylation status is still to be debated. MATERIAL AND METHODS Population based retrospective study that examined all adult patients in South-Eastern Norway that underwent resection for IDH wildtype glioblastoma between January 2019 and December 2021. Extent of resection (EOR) was classified according to RANO resect classification and MGMT-promotor methylation status by pyrosequencing-qPCR. RESULTS The study included 281 patients. MGMT-promotor methylated patients (MGMT+) had a median OS of 18.4 months compared to 13.1 months in MGMT-unmethylated (MGMT-) patients (p&lt;0.0001). Patients with supramaximal resection had a median OS of 20.4 months compared to 14.9 months (p&lt;0.01) with maximal resection. For patients with supramaximal resection we found no significant difference in median OS (25.5 vs. 18.3 months (p=0.24)) dependent on MGMT-status. Separated analysis between MGMT-status and EOR showed a median survival of 18.3, 13.4 (p&lt;0.001), and 8.5 (p&lt;0.001) months for MGMT-, and 25.5, 18.4 (p=.99), and 9.0 (p&lt;0.001) months for MGMT+ in patients where supramaximal-, maximal-, and submaximal resection was achieved, respectively. CONCLUSIONS Patients with supramaximal resection and MGMT+ have a 50% 2-years survival probability. In patients where supramaximal resection was achieved, survival benefit was not dependent on MGMT-status. There was a significant improved survival in MGMT- patients between supramaximal and maximal resection, that was not present for MGMT+ patients. Intraoperative molecular diagnosis has the potential to guide the surgical strategy dependent on MGMT-promotor methylation status, especially in tumors where supramaximal resection has a higher risk of new neurological deficits.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.1126</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii284-viii284
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae165_1126
source Oxford University Press Journals All Titles (1996-Current)
title SURG-47. SUPRAMAXIMAL RESECTION IMPROVES OVERALL SURVIVAL IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SURG-47.%20SUPRAMAXIMAL%20RESECTION%20IMPROVES%20OVERALL%20SURVIVAL%20IN%20PATIENTS%20WITH%20MGMT-UNMETHYLATED%20GLIOBLASTOMA&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Mendoza%20Mireles,%20Eduardo%20Erasmo&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii284&rft.epage=viii284&rft.pages=viii284-viii284&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.1126&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.1126%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.1126&rfr_iscdi=true